Friday, 19 Jul 2019

You are here

Sjögren's Syndrome Differs in Minorities

Minority groups in the U.S. have differing rates of Sjögren's syndrome (SS) and exhibit distinct clinical patterns of the disease, a large cross-sectional study revealed.

The percentage of American Indians in a SS cohort of 610 patients was much higher than expected, at 25.3%, whereas the percentage of African Americans was lower, at 3.1%, according to Astrid Rasmussen, MD, PhD, of the Oklahoma Medical Research Foundation in Oklahoma City, and colleagues.

In addition, American Indians had higher levels of disease activity and more extraglandular manifestations, whereas African Americans had a symptom pattern associated with subsequent lymphoma development, they reported in Arthritis Care & Research.

SS is a multifaceted autoimmune disease characterized by dysfunction of the salivary, lacrimal, and other exocrine glands, the presence of autoantibodies, and extraglandular manifestations such as arthritis, lymphadenopathy, vasculitis, and lymphoma. The diagnosis can be difficult because it typically requires multidisciplinary involvement and there is no gold standard test. Therefore, "SS is frequently misdiagnosed, underdiagnosed, or diagnosed at late stages of the disease," the researchers observed.

Moreover, little is known about epidemiology and differences among minority ethnic groups, who often are disproportionately affected by autoimmune diseases.

Accordingly, Rasmussen's group analyzed data from the Oklahoma Sjögren's Syndrome Center of Research Translation, which included almost 1,700 individuals evaluated for sicca symptoms from 2005 to 2017 from the Oklahoma Medical Research Foundation, the University of Minnesota in Minneapolis, Cedars-Sinai Medical Center in Los Angeles, and the Carolinas Medical Center in Charlotte, North Carolina.

Their analysis included 426 patients self-identified as having European heritage, 164 American Indians, and 20 African Americans. (Other groups such as Asians and Hispanics were not included in the analysis because the numbers were too few.)

Whereas the American Indians comprised one-quarter of the SS cohort, their percentage of the overall population was substantially lower in Oklahoma, at 11.9%, and in the U.S. as a whole, at 1.41%. And whereas African Americans represented <5% of the SS cohort, they comprised 7.3% of the Oklahoma population and 12.6% of the overall U.S. population.

Regarding disease characteristics, fewer American-Indian patients exhibited decreased salivary flow (61.4% vs 70.1%) and tear production (44.5% vs 60.3%) compared with patients of European descent. They also had lower rates than the European ancestry group of autoantibodies including anti-Ro/SSA (OR 0.59, 95% CI 0.41-0.85), anti-La/SSB (OR 0.42, 95% CI 0.28-0.62), and rheumatoid factor (OR 0.58, 95% CI 0.39-0.88). African Americans more often had hypergammaglobulinemia than patients with European ancestry (52.6% vs 23.6%) or American Indians (14.6%).

African Americans also more often had elevated erythrocyte sedimentation rates (47.1%) than the European ancestry group (18.4%) or American Indians (23.2%).

For extraglandular manifestations, articular disease was more common in both American Indians (OR 2.26, 95% CI 1.46-3.47) and African Americans (OR 3, 95% CI 1.16-7.66) than the European ancestry group. Glandular involvement such as parotid swelling was more common among American Indians and African Americans than Europeans, and hematologic abnormalities were more frequently seen in African Americans.

"We found marked differences in the susceptibility to SS in the different races; American Indians are affected at a higher rate than expected based on their proportion of the general population, and African Americans are under-represented ... in comparison to the general population," the researchers wrote.

A similar pattern has been seen with rheumatoid arthritis. Among Caucasians, the annual incidence worldwide has been estimated at 0.5% to 1%, but reportedly is as low as 0.1% among rural residents of Africa and as high as 5% in certain American Indian tribes such as the Pima and Chippewa.

Many studies have documented disparities in access to care and socioeconomic status for minority groups and have linked these factors with poorer outcomes. This may have contributed to some of the differences observed in the current study, and although American Indians tend to have lower socioeconomic status than whites, they do have access to Indian Health Services and other specialty care and may more easily obtain referrals.

"Thus, we hypothesize that the observed differences in disease frequency and phenotype are at least in part due to bona fide biological factors (i.e., population-specific genotypes underlying dysregulation of differing pathways), rather than being purely attributable to marginalization and social determinants," Rasmussen and colleagues wrote.

The observation that American Indian patients in this cohort had fewer of the most prominent SS symptoms and clinical clues such as salivary and lacrimal dysfunction and typical autoantibodies may result in a delay or lack of diagnosis and treatment. Thus, a heightened suspicion is needed in this population.

Similarly, the triad of hypergammaglobulinemia, elevated erythrocyte sedimentation rate, and parotid swelling observed among African Americans has been associated with lymphomagenesis, so more intensive surveillance for malignancy is warranted in this group, the researchers concluded.

A study limitation was its cross-sectional design.

The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Cardiovascular Disease Increased in Hospitalized Lupus Patients

Systemic lupus erythematosus (SLE) patients who are hospitalized have an increased prevalence of atherosclerotic cardiovascular disease (ASCVD) and its individual phenotypes of coronary artery disease (CAD), peripheral artery disease (PAD), and cerebrovascular disease. 

Pregnancy Outcomes Improve in Lupus

Pregnancy for patients with lupus has long been considered high risk and associated with both medical and obstetric complications, but outcomes have improved over the last 2 decades and continue to improve. The large decline in in-hospital maternal mortality was greater for lupus pregnancies than for non-lupus pregnancies. Findings from a retrospective cohort study are published in Annals of Internal Medicine.

Blinded by the Use of Antimalarials in Lupus?

Editor's note: July 1 - 5, RheumNow is running the best of EULAR 2019 meeting. Hydroxychloroquine (HCQ) will decrease SLE flares improve lipids, decrease clots, improve survival, augment the response to mycophenolate and are the cornerstone of treatment as per the SLE EULAR guidelines presented at EULAR 2019 in Madrid and also published in ARD. But, if you prescribe them long term, will your patients go blind?

Disparities in Lupus Survival

MMWR has published the outcomes from the Georgia Lupus Registry between 2002 and 2016, finding that black women were not only more likely to die from lupus than white lupus patients; but they died on average 13 years earlier (mean age 51.8 and 52.3 years, respectively) than whites (mean age 64.4 and 65.0 years, respectively). Black women with lupus were 3.34 times more likely to die than black women in the general population, while white women with lupus were 2.43 times more likely to die than white women in the general population. None of the white women with lupus died within 5 years of diagnosis, while mortality was elevated for black women from the date of diagnosis on.

DMARD Success in Myositis-Related Interstitial Lung Disease

It is estimated that up to 50% of patients with idiopathic inflammatory myopathy will be complicated by interstitial lung disease, and having ILD may impart a poor prognosis. A recent review of the Johns Hopkins myositis-related ILD cohort has shown that azathioprine and mycophenolate mofetil use is associated improved lung function and less prednisone use.